Fundamental Cause Theory, Technological Innovation, and Health Disparities: The Case of Cholesterol in the Era of Statins
Open Access
- 1 September 2009
- journal article
- research article
- Published by SAGE Publications in Journal of Health and Social Behavior
- Vol. 50 (3) , 245-260
Abstract
Although fundamental cause theory has been highly influential in shaping the research literature on health disparities, there have been few empirical demonstrations of the theory, particularly in dynamic perspective. In this study, we examine how income disparities in cholesterol levels have changed with the emergence of statins, an expensive and potent new drug technology. Using nationally representative data from 1976 to 2004, we find that income gradients for cholesterol were initially positive, but then reversed and became negative in the era of statin use. While the advantaged were previously more likely to have high levels of cholesterol, they are now less likely. We consider our case study against a broader theoretical framework outlining the relationship between technology innovation and health disparities. We find that the influence of technologies on socioeconomic disparities is subject to two important modifiers: (1) the nature of the technological change and (2) the extent of its diffusion and adoption.Keywords
This publication has 32 references indexed in Scilit:
- Did Socioeconomic Inequalities in Morbidity and Mortality Change in the United States over the Course of the Twentieth Century?Journal of Health and Social Behavior, 2007
- Trends in Serum Lipids and Lipoproteins of Adults, 1960-2002JAMA, 2005
- Toward Some Fundamentals of Fundamental Causality: Socioeconomic Status and Health in the Routine Clinic Visit for DiabetesAmerican Journal of Sociology, 2005
- “Fundamental Causes” of Social Inequalities in Mortality: A Test of the TheoryJournal of Health and Social Behavior, 2004
- Social Epidemiology and the Fundamental Cause Concept: On the Structuring of Effective Cancer Screens by Socioeconomic StatusThe Milbank Quarterly, 1998
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- Twelve-year trends in cardiovascular disease risk factors in the Minnesota Heart Survey. Are socioeconomic differences widening?Archives of internal medicine (1960), 1997
- Dietary Intake Patterns and Sociodemographic Factors in the Atherosclerosis Risk in Communities StudyPreventive Medicine, 1994
- Employment grade and coronary heart disease in British civil servants.Journal of Epidemiology and Community Health, 1978
- Changing social-class distribution of heart disease.BMJ, 1978